Treats osteoporosis in postmenopausal women. ANDA 90520, held by Hikma. Alendronate Sodium.
As of Nov 16, 2026, ANDA 90520 (Alendronate Sodium), held by Hikma, was first approved by FDA on Feb 25, 2013, with 5 approved supplements and 0 published complete response letters.
Alendronate Sodium Oral Solution is a bisphosphonate indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 25, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Alendronate SodiumEQ 70MG BASE/75ML · solution;oral | Alendronate Sodium | Rx |
| Feb 3, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 28, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 28, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 19, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 23, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 25, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters